Next, the IMvigor210 cohort, an immune-related cohort for the treatment of BLCA, was analyzed to further investigate the potential capability of FGL2 in forecasting the clinical response to immunotherapy. Here, FGL2 is linked to bladder transitional cell carcinoma.